Celldex Therapeutics (CLDX) Gains from Investment Securities (2010 - 2026)

Celldex Therapeutics' Gains from Investment Securities history runs 17 years deep, the most recent figure standing at $78100.0 for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 93.32% year-over-year to $78100.0; the TTM figure through Mar 2026 stood at $78100.0 (up 93.32% YoY), while the FY2025 annual figure was $9.1 million, up 21.14% from the prior year.
• Gains from Investment Securities was $78100.0 for Q1 2026 at Celldex Therapeutics, down from $9.2 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $9.2 million in Q3 2025 to a low of -$4000.0 in Q4 2024.
• Historically, Gains from Investment Securities has averaged $2.1 million across 5 years, with a median of $634237.0 in 2023.
• The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities soared 1003494.32% in 2022, then slumped 100.06% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at -$1000.0 in 2022, then soared by 637992.4% to $6.4 million in 2023, then tumbled by 100.06% to -$4000.0 in 2024, then soared by 229554.3% to $9.2 million in 2025, then sank by 99.15% to $78100.0 in 2026.
• The last three Gains from Investment Securities figures came in at $78100.0 (Q1 2026), $9.2 million (Q3 2025), and $203201.0 (Q2 2025), per Business Quant data.